Drugs.com

DECEMBER 19, 2023

19, 2023 -- Early results from a trial of a new kidney disease medication show it significantly reduces levels of a urine marker of kidney damage.The experimental drug -- called BI 690517 for now -- cut levels of the liver protein. TUESDAY, Dec.

Disease 264

Disease Drugs Trials 264

BioPharma Drive: Drug Pricing

DECEMBER 6, 2023

The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.

FDA Approval 301

FDA Approval Disease FDA Drugs 301

Drugs.com

APRIL 21, 2025

MONDAY, April 21, 2025 -- An oral chemotherapy drug can safely and effectively manage sickle cell disease in children, a new study says.Children taking hydroxyurea had fewer ER visits and spent fewer days in the hospital compared to kids not taking.

Disease 195

Disease Hospitals Drugs 195

BioPharma Drive: Drug Pricing

AUGUST 21, 2024

Backed by $300 million from investors that include Viking Global Investors and Sequoia Capital, GondolaBio will inherit several BridgeBio drug programs.

Disease 284

Disease Drugs 284

Drugs.com

MARCH 15, 2024

FRIDAY, March 15, 2024 -- Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.The condition is.

FDA Approval 246

FDA Approval Disease FDA Drugs 246

Science Daily: Pharmacology News

JUNE 18, 2024

Tests, in mice, of a drug developed by the researchers showed that regulatory T cells can be attracted to specific body parts, boosted in number, and activated to suppress immune response and rebuild tissue. Clinical trials in humans are now planned.

Treatment 338

Treatment Immune Response Disease Clinical Trials 338

Science Daily: Pharmacology News

FEBRUARY 17, 2025

The findings demonstrate the potential of this technology to pave the way for future treatments for a wide range of conditions such as Alzheimer's disease, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

RNA 285

RNA Treatment Disease Drugs 285

Drugs.com

OCTOBER 28, 2024

28, 2024 -- The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows.Patients taking semaglutide -- the active agent in Ozempic and Wegovy -- had as much as a 52% reduction in kidney damage, as. MONDAY, Oct.

Disease 278

Disease Drugs 278

Science Daily: Pharmacology News

APRIL 16, 2025

Drugs like Ozempic, other blood sugar-reducing medications, may stave off dementia.

Disease 277

Disease Drugs 277

BioPharma Drive: Drug Pricing

JUNE 11, 2024

Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August. The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis.

Disease 284

Disease FDA Drugs Treatment 284

Drugs.com

MARCH 22, 2024

FRIDAY, March 22, 2024 -- Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, U.S. Food and Drug Administration approved drugmaker Novo. officials announced Thursday.The move comes after the U.S.

Disease 298

Disease Drugs 298

BioPharma Drive: Drug Pricing

DECEMBER 17, 2024

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

Disease 274

Disease Therapies Drugs 274

BioPharma Drive: Drug Pricing

FEBRUARY 12, 2024

The proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a chronic liver disease called primary biliary cholangitis.

Disease 236

Disease FDA Drugs 236

Drugs.com

JUNE 10, 2024

MONDAY, June 10, 2024 -- An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests. The drug under development, survodutide, helped up to 83% of patients gain real improvements.

Disease 264

Disease Trials Drugs 264

BioPharma Drive: Drug Pricing

APRIL 16, 2025

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.

Disease 249

Disease Drugs 249

Drugs.com

MARCH 15, 2024

FRIDAY, March 15, 2024 -- Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday. The condition is.

FDA Approval 214

FDA Approval Disease FDA Drugs 214

Drugs.com

JANUARY 11, 2024

doctors are prescribing antifungal creams to patients with skin complaints at rates so high they could be contributing to the rise of drug-resistant infections, new research shows.These are "severe. THURSDAY, Jan. 11, 2024 -- U.S.

Doctors 290

Doctors Disease Drugs Research 290

Drugs.com

DECEMBER 27, 2024

27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. FRIDAY, Dec. A new study published recently in the journal Gut shows children with Crohn's who were prescribed.

Disease 246

Disease Drugs 246

Drugs.com

MARCH 7, 2024

THURSDAY, March 7, 2024 -- There's more good news around the diabetes and weight-loss drug Ozempic: It might help ease fatty liver disease in people living with HIV, new research shows.Six months of weekly injections of Ozempic (semaglutide).

Disease 244

Disease Research Drugs 244

Drugs.com

NOVEMBER 2, 2023

1, 2023 -- A new gene therapy for sickle cell disease was deemed safe by a U.S. Food and Drug Administration advisory panel on Tuesday, paving the way for full approval by early December. WEDNESDAY, Nov. The FDA had already decided that the.

Therapies 263

Therapies FDA Disease Drugs 263

BioPharma Drive: Drug Pricing

APRIL 17, 2025

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23.

Licensing 144

Licensing Licensing Disease Drugs 144

Drugs.com

AUGUST 26, 2024

24, 2024 -- A type of drug used to treat Alzheimer’s disease appears to slow the progression of Lewy body dementia, the brain disease that afflicted comedian Robin Williams prior to his suicide.Cholinesterase inhibitors prevent the b. MONDAY, Aug.

Drugs 290

Drugs Disease 290

Collaborative Drug

FEBRUARY 7, 2024

Upcoming Webinar 3-21 24: Interdisciplinary Pathways in Medicine: Neurodegenerative Research and Drug Discovery

Research 286

Research Disease Drugs 286

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2023

Much anticipated clinical trial data for Immunovant’s experimental FcRn inhibitor could catalyze business development decisions for its parent, Roivant Sciences.

Clinical Trials 273

Clinical Trials Disease Science Trials 273

Drugs.com

SEPTEMBER 18, 2024

18, 2024 -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis. WEDNESDAY, Sept.

FDA 290

FDA Drugs Treatment Disease 290

Drugs.com

JULY 2, 2024

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early.

FDA Approval 290

FDA Approval Clinical Trials FDA Drugs 290

Collaborative Drug

AUGUST 29, 2023

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

Small Molecule 246

Small Molecule Treatment Disease Research 246

Science Daily: Pharmacology News

MARCH 19, 2025

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study.

Clinical Trials 313

Clinical Trials Drugs Trials Treatment 313

BioPharma Drive: Drug Pricing

MARCH 26, 2024

Merck is couting on Winrevair, which it acquired by buying Acceleron Pharma, to help soften the blow when Keytruda loses patent protection later this decade.

FDA Approval 292

FDA Approval Disease FDA Drugs 292

BioPharma Drive: Drug Pricing

JUNE 2, 2024

Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.

Drugs 302

Drugs Treatment Disease 302

Covalent Modifiers

SEPTEMBER 18, 2024

Wherein JNK3 is specifically expressed in brain and emerges as therapeutic target, especially for neurodegenerative diseases. However, developing JNK3 selective inhibitors as chemical probes to investigate its therapeutic potential in diseases remains challenging.

Small Molecule 211

Small Molecule Disease Treatment Drugs 211

BioPharma Drive: Drug Pricing

MARCH 14, 2024

Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.

FDA Approval 326

FDA Approval FDA Drugs Disease 326

Drugs.com

FEBRUARY 6, 2025

Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with. THURSDAY, Feb. 6, 2025 -- The U.S.

FDA Approval 277

FDA Approval Disease FDA Treatment 277

BioPharma Drive: Drug Pricing

JUNE 26, 2024

Obesity drugs like Wegovy are proving useful in many other diseases. Polycystic ovary syndrome, a chronic condition that can cause infertility, may be one.

Treatment 313

Treatment Drugs Disease 313

BioPharma Drive: Drug Pricing

AUGUST 29, 2023

A broadened clearance for Reblozyl in myelodysplastic syndromes should help Bristol Myers offset the looming loss of revenue from top-selling medicines set to soon lose market exclusivity.

FDA Approval 293

FDA Approval Disease FDA Marketing 293

BioPharma Drive: Drug Pricing

FEBRUARY 5, 2024

The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

Drugs 318

Drugs Disease 318

BioPharma Drive: Drug Pricing

NOVEMBER 1, 2024

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.

Drugs 301

Drugs Disease 301